Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Trading of Zogenix Common Stock Halted

12/07/2012 | 08:00am US/Eastern

FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application

Zogenix to Host Conference Call at 6:30 pm ET Today

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced that NASDAQ halted trading of the company's common stock on December 7, 2012. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting today to review the Company's New Drug Application (NDA) for Zohydro™ ER (hydrocodone bitartrate extended-release capsules).

Conference Call & Webcast

Zogenix will host a conference call to discuss the outcome of the AADPAC meeting today, Friday, December 7, 2012 at 6:30 p.m. ET (3:30 p.m. PT). To participate, please dial (800) 299-9086 (U.S.) or (617) 786-2903 (International); participant passcode: 21970283. To access the live webcast please visit the Zogenix Investor Relations website at http://ir.zogenix.com.  

The conference call will be hosted by Chief Executive Officer Roger L. Hawley and President and Chief Operating Officer Stephen J. Farr, Ph.D.

A replay of the conference call will be available beginning December 7, 2012 at 8:30 p.m. ET (5:30 p.m. PT) until December 14, 2012, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 27116437. A replay of the webcast will also be accessible on the Investor Relations website for one month, through January 10, 2013.

About Anesthetic and Analgesic Drug Products Advisory Committee

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human anesthetic and analgesic drug products and makes appropriate recommendations to the Commissioner of Food and Drugs. The AADPAC provides FDA with independent expert advice and recommendations, however, the final decision regarding approval is made by FDA.

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZohydroTM ER (hydrocodone bitartrate) is an oral, novel extended-release formulation of various strengths of hydrocodone without acetaminophen intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, ReldayTM, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ®, DosePro ®, ReldayTM and ZohydroTM ER are trademarks of Zogenix, Inc.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Emily Poe | WCG
         212.301.7183 | epoe@wcgworld.com
Zogenix
distributed by
React to this article
Latest news
Date Title
02:08a MANCHESTER UNITED : United fail their forfeitness test
02:08a SINGAPORE TELECOMMUNICATIONS : Singtel, Sony Pictures Television and Warner Bros. Entertainment establish start-up to offer OTT video to Asia
02:07a LLOYDS BANKING : FIRST we learn the Chilcot
02:06a APPLE : Of my eye
02:05a LLOYDS BANKING : FIRST we learn the Chilcot
02:05a LLOYDS BANKING : No Gray day for Cherries
02:04a APPLE : Of my eye
02:04a MANCHESTER UNITED : CAMBRIDGE UNITED have never been ; SPORT CONFIDENTIAL
02:04a MANCHESTER UNITED : ANGEL DI MARIA could do ; CONFIDENTIAL with DEAN JONES SPORT
02:02a APPLE : Of my eye
Latest news
Advertisement
Hot News 
BANCO ESPIRITO SANTO : Drought woes spread to another Brazilian state
BERKELEY MINERAL RESOURCES : Obsidian IR
Gulf Resources Announced Finding of Natural Gas Resources Under Its Bromine Well in Sichuan Area
RAMBLER METALS & MINING : Implements Revised Plan at the Ming Copper-Gold Mine
UNISYS : posts 4Q profit
Most Read News
01/31 U.S. regulators recall 2.1 million vehicles in new air bag issue
01/31 Lafarge SA, Holcim near deal to sell $7 billion in assets to CRH - WSJ
01:19a GM and China’s SAIC to push into Indonesia with no-frills vans
01/31 LAS VEGAS SANDS : Price Target Lowered to $72.00 at Stifel Nicolaus (LVS)
01/31 Firms prepare for new tax rules as China vows crackdown
Most recommended articles
01:20a GM and China’s SAIC to push into Indonesia with no-frills vans
01:12a Islamic finance looks to outgrow bad habits as it expands
01/31 China official services PMI at one-year low in January
01/31 China factory sector jolts by shrinking in January
01/31 China factory sector jolts by shrinking in January
Dynamic quotes  
ON
| OFF